je.st
news
FDA rejects Amarin appeal on Vascepa trial design, shares slump
2014-01-22 11:50:08| Biotech - Topix.net
Amarin Corp Plc's shares fell more than 26 percent after U.S. health regulators rejected a preset testing process that was critical to the company seeking broader use of its blood fat-lowering drug.
Tags: design
trial
shares
appeal
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||